Listen to this article · 7 min listen

The huge sums of money flowing into AI-powered healthcare don’t always produce the promised results. For the M&A teams, board directors, and investors writing the checks, the anatomy of a massive digital health write-down is a critical lesson in valuation and integration. These expensive failures all point to one simple truth: you only earn a platform multiple when your operating results prove you’ve successfully integrated the acquisition and are delivering real value.

The Teladoc/Livongo Case: A Reference Point for Integration Challenges

Teladoc’s acquisition of Livongo is the poster child for the pitfalls hidden in digital care multiples. Back in 2020, Teladoc spent $18.5 billion on Livongo SEC filing detailing Teladoc’s acquisition of Livongo, a staggering investment that was followed by a $13.7 billion impairment charge just two years later CNBC report on Teladoc’s impairment charge. This write-down is the anchor we use to analyze post-merger ROI because it so clearly shows what happens when things go wrong. The problem wasn’t the concept of digital health. The problem was the underwriting assumed an integration that the company’s operating results never delivered. Buyers will pay a platform multiple based on the promise of synergies, market expansion, and a smooth blend of technologies. But when you look at the Teladoc/Livongo Post-Merger ROI Assessment, it’s clear the anticipated integration and value creation didn’t happen at the scale they projected. That gap between projection and reality costs buyers billions, and it’s why you have to do rigorous due diligence on operational integration capabilities before you ever put a price on a deal.

VillageMD/Walgreens and Oak Street Health (CVS): A Recurring Pattern

The Teladoc/Livongo story wasn’t a one-off, it’s a pattern we’re seeing all over digital health. VillageMD/Walgreens ran the same play in the clinic space. Walgreens pumped $5.2 billion into VillageMD, then announced a $5.8 billion impairment in 2024 Fierce Healthcare report on Walgreens’ VillageMD impairment. It’s the same scenario: a huge capital investment that didn’t generate the expected financial returns, which ended in a massive write-down. We’re seeing a third version of this with CVS’s $10.6 billion acquisition of Oak Street Health Report on CVS’s acquisition of Oak Street Health. That deal was followed by a $5.7 billion goodwill impairment charge in 2025, showing the same bet on integrated care and platform multiples, and the same difficulties in actually making it pay off. All these cases show that the challenge isn’t with the value of primary care itself, but with the brutal reality of executing an integration and realizing the projected cost savings.

Underwriting Assumptions vs. Operational Reality

The real lesson from these huge write-downs is that the business models for digital health and value-based care didn’t fail. What failed was the underwriting process. The deal models were built on an assumed level of integration and teamwork that the actual operating results couldn’t support. So if you’re an investor, on an M&A team, or a board member pricing a platform deal, you have to tear apart the assumptions about how the acquired company will fit into your structure, how its technology will interoperate with yours, and how its care model will scale. People consistently underestimate how hard it is to get true interoperability and cultural alignment, but that’s where all the promised value is supposed to come from. Without a clear, executable roadmap for integrating patient data, clinical workflows, and tech infrastructure, the platform multiple is just a promise. A buyer should be testing any program that hasn’t been run at the planned scale, demanding demonstrable, scalable proof of integration before paying a premium.

Measuring Healthcare AI ROI: Beyond Projections to Peer-Reviewed Outcomes

All this red ink makes the case for independently validated ROI pretty clear. Look at Hello Heart, for example. They have a peer-reviewed study showing $1,800 in per-member savings and a 47% reduction in inpatient admissions Peer-reviewed study on Hello Heart’s ROI. That kind of verifiable financial outcome is a world away from the fuzzy projections that prop up so many platform multiples. This is the kind of evidence M&A teams and investors need to find AI healthcare applications that actually deliver. To measure healthcare AI ROI effectively, you have to get past vendor sales pitches and demand a framework built on independently published financial outcomes. That means digging into exactly how cost savings are realized and how clinical improvements translate into tangible financial benefits. The focus needs to shift from AI’s potential to its proven impact, especially when you’re thinking about the total cost of care and long-term profitability.

The Integration Test: A Buyer’s Framework for Future Deals

Before you sign off on the next big platform deal, you need to run a rigorous integration test. This isn’t about theoretical synergies. It’s about the messy details of operational execution. You need to ask some hard questions.

  • Demonstrable Integration Plan: Do you have a detailed, actionable plan for integrating the tech, data, and workflows? Is it backed by a track record of doing this successfully before? Show me.
  • Scalability of Operating Results: Have the program’s operating results actually been proven at a scale that’s relevant to your plans? Or are we basing billion-dollar projections on a tiny pilot program?
  • Cultural and Operational Fit: How will you merge the two company cultures and operating models without them destroying each other? What specific mechanisms (not just good intentions) are in place to manage friction?
  • Verifiable ROI Methodology: Does this company have a solid, peer-reviewed way to measure its ROI? And can those outcomes be verified by someone who doesn’t work there?
  • Data Interoperability and Governance: What is the precise strategy for data integration? I need to see the plan for ensuring smooth data exchange that meets all the relevant privacy and security standards like HIPAA, HITRUST, and SOC 2. The largest digital health write-downs are an expensive education for underwriters. They teach us that a platform multiple is a premium paid for integration. Without a clear, verifiable path to achieve that integration at scale, the investment is a massive gamble. By grounding valuations in independently validated ROI and putting integration plans under a microscope, M&A teams, board directors, and healthcare investors can start making much smarter decisions.

Frequently Asked Questions

What is the primary lesson for investors from the digital health write-downs discussed?

The primary lesson is that platform multiples are only justified when recorded operating results demonstrate successful integration and sustained value delivery. The write-downs highlight a discrepancy between projected integration and value creation and what was actually realized post-acquisition, emphasizing the need for rigorous due diligence on operational integration capabilities.

What is the core issue identified in the Teladoc/Livongo case and similar write-downs?

The core issue was an underwriting assumption of integration and operational synergy that the recorded operating results did not deliver. Buyers often pay a platform multiple based on projected synergies and expanded market reach, but the anticipated integration and subsequent value creation did not materialize at the scale initially projected, leading to significant impairment charges.

What should M&A teams and investors scrutinize before paying a platform multiple for digital health deals?

M&A teams and investors must scrutinize assumptions about how acquired entities will integrate into existing structures, how technologies will interoperate, and how new care models will scale within the acquiring organization’s operational framework. A critical aspect often overlooked is the difficulty in achieving true interoperability and cultural alignment, which are essential for unlocking promised value.

How can investors better assess the ROI of healthcare AI applications to avoid write-downs?

Investors should move beyond vendor-claimed projections and prioritize independently published financial outcomes and peer-reviewed results. Verifiable financial outcomes, such as those demonstrated by Hello Heart, provide a stark contrast to unfulfilled projections and are crucial for identifying AI healthcare applications with the highest ROI use cases.